An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease.

Trial Profile

An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2012

At a glance

  • Drugs FX 125L (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 26 Apr 2012 Official Title amended, primary endpoints added and planned number of patients (119) added as reported by European Clinical Trials Database.
    • 26 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2011-005036-26).
    • 26 Apr 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top